Entyvio(潰瘍性大腸炎)：市場分析と予測（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 16
3.2.1 Quality of Life 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 23
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
6 Opportunity and Unmet Need 30
6.1 Overview 30
6.2 Unmet Needs 31
6.2.1 Curative Therapy for Severe UC Patients 31
6.2.2 Diagnostic Markers for Disease Severity 31
6.2.3 Personalized Therapy 32
6.2.4 A Replacement for Steroids 32
6.2.5 Novel Oral Drug Formulations 33
6.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 34
6.2.7 Improved Management of Infectious Adverse Events 34
6.3 Unmet Needs Gap Analysis 35
6.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 36
6.5 Predictors of Medically-Refractory Disease 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising Drugs in Clinical Development 38
8 Entyvio (vedolizumab) 40
8.1 Overview 40
8.2 Efficacy 42
8.3 Safety 44
8.4 Dosing and Formulation 46
8.5 Potential Clinical Positioning 46
8.6 Potential Commercial Positioning 47
8.7 Pricing and Reimbursement 48
8.8 SWOT Analysis 49
8.9 Forecast 49
9 Appendix 51
9.1 Bibliography 51
9.2 Abbreviations 53
9.3 Methodology 57
9.4 Forecasting Methodology 57
9.4.1 Diagnosed UC Patients 57
9.4.2 Percent Drug-Treated Patients 58
9.4.3 General Pricing Assumptions 58
9.4.4 Generic Erosion 59
9.4.5 Pricing of Pipeline Agents 59
9.5 Physicians and Specialists Included in This Study 60
9.6 Primary Research – Prescriber Survey 61
9.7 About the Authors 62
9.7.1 Author 62
9.8 About GlobalData 63
9.9 Disclaimer 63